Base de dados : MEDLINE
Pesquisa : D02.241.081.251.240 [Categoria DeCS]
Referências encontradas : 1713 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 172 ir para página                         

  1 / 1713 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743082
[Au] Autor:Rodrigues GB; Oliveira EE; Junior FJBM; Santos LAMD; Oliveira WH; França MER; Lós DB; Gabínio BM; de Lira FCML; Peixoto CA
[Ad] Endereço:Laboratório de Ultraestrutura, Instituto Aggeu Magalhães - FIOCRUZ, Recife, Brazil; Programa de Pós-graduação em Ciências Biológicas, Centro de Biociências, Universidade Federal de Pernambuco - UFPE, Recife, Brazil.
[Ti] Título:Characterization and evaluation of nanoencapsulated diethylcarbamazine in model of acute hepatic inflammation.
[So] Source:Int Immunopharmacol;50:330-337, 2017 Sep.
[Is] ISSN:1878-1705
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Previous studies from our laboratory have demonstrated that Diethylcarbamazine (DEC) is a potent anti-inflammatory drug. The aim of the present study was to characterize the nanoencapsulation of DEC and to evaluate its effectiveness in a model of inflammation for the first time. C57BL/6 mice were divided into six groups: 1) Control; 2) Carbon tetrachloride (CCl4); 3) DEC 25mg/kg+CCl4; 4) DEC 50mg/kg+CCl4; 5) DEC-NANO 05mg/kg+CCl4 and 6) DEC-NANO 12.5mg/kg+CCl4. Liver fragments were stained with hematoxylin-eosin, and processed for Western blot, ELISA and immunohistochemistry. Serum was also collected for biochemical measurements. Carbon tetrachloride induced hepatic injury, observed through increased inflammatory markers (TNF-α, IL-1ß, PGE2, COX-2 and iNOS), changes in liver morphology, and increased serum levels of total cholesterol, triglycerides, TGO and TGP, LDL, as well as reduced HDL levels. Nanoparticles containing DEC were characterized by diameter, polydispersity index and zeta potential. Treatment with 12.5 nanoencapsulated DEC exhibited a superior anti-inflammatory action to the DEC traditional dose (50mg/kg) used in murine assays, restoring liver morphology, improving serological parameters and reducing the expression of inflammatory markers. The present formulation of nanoencapsulated DEC is therefore a potential therapeutic tool for the treatment of inflammatory hepatic disorders, permitting the use of smaller doses and reducing treatment time, while maintaining high efficacy.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Cápsulas/administração & dosagem
Dietilcarbamazina/uso terapêutico
Hepatite/tratamento farmacológico
Nanoestruturas/administração & dosagem
[Mh] Termos MeSH secundário: Doença Aguda
Animais
Citocinas/metabolismo
Modelos Animais de Doenças
Sistemas de Liberação de Medicamentos
Seres Humanos
Mediadores da Inflamação/metabolismo
Metabolismo dos Lipídeos
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Capsules); 0 (Cytokines); 0 (Inflammation Mediators); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE


  2 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29064364
[Au] Autor:Lammie PJ; Eberhard ML; Addiss DG; Won KY; Beau de Rochars M; Direny AN; Milord MD; Lafontant JG; Streit TG
[Ad] Endereço:Centers for Disease Control and Prevention, Atlanta, Georgia.
[Ti] Título:Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti.
[So] Source:Am J Trop Med Hyg;97(4_Suppl):71-75, 2017 Oct.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Research provides the essential foundation of disease elimination programs, including the global program to eliminate lymphatic filariasis (GPELF). The development and validation of new diagnostic tools and intervention strategies, critical steps in the evolution of GPELF, required a global effort. Lymphatic filariasis research in Haiti involved many partners and was directly linked to the development of the national elimination program and to the success achieved to date. Ongoing research efforts involving many partners will continue to be important in resolving the challenges faced by the program today in its final efforts to achieve elimination.
[Mh] Termos MeSH primário: Erradicação de Doenças
Filariose Linfática/prevenção & controle
Linfedema/terapia
[Mh] Termos MeSH secundário: Dietilcarbamazina/uso terapêutico
Filariose Linfática/complicações
Filariose Linfática/tratamento farmacológico
Filaricidas/uso terapêutico
Haiti
Seres Humanos
Linfedema/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Filaricides); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.16-0669


  3 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29059186
[Au] Autor:Kar SK; Dwibedi B; Das BK; Agrawala BK; Ramachandran CP; Horton J
[Ad] Endereço:Director of Medical Research, IMS & Sum Hospital, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India.
[Ti] Título:Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment.
[So] Source:PLoS Negl Trop Dis;11(10):e0005631, 2017 Oct.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Once interruption of transmission of lymphatic filariasis is achieved, morbidity prevention and management becomes more important. A study in Brugia malayi filariasis from India has shown sub-clinical lymphatic pathology with potential reversibility. We studied a Wuchereria bancrofti infected population, the major contributor to LF globally. METHODS: Children aged 5-18 years from Odisha, India were screened for W. bancrofti infection and disease. 102 infected children, 50 with filarial disease and 52 without symptoms were investigated by lymphoscintigraphy and then randomized to receive a supervised single oral dose of DEC and albendazole which was repeated either annually or semi-annually. The lymphatic pathology was evaluated six monthly for two years. FINDINGS: Baseline lymphoscintigraphy showed abnormality in lower limb lymphatics in 80% of symptomatic (40/50) and 63·5% (33/52) of asymptomatic children. Progressive improvement in baseline pathology was seen in 70·8, 87·3, 98·6, and 98·6% of cases at 6, 12, 18, and 24 months follow up, while in 4·2, 22·5, 47·9 and 64·8%, pathology reverted to normal. This was independent of age (p = 0·27), symptomatic status (p = 0·57) and semi-annual/bi-annual dosing (p = 0·46). Six of eleven cases showed clinical reduction in lymphedema of legs. INTERPRETATION: A significant proportion of a young W. bancrofti infected population exhibited lymphatic pathology which was reversible with annual dosage of DEC and albendazole. This provides evidence for morbidity prevention & treatment of early lymphedema. It can also be used as a tool to improve community compliance during mass drug administration. TRIAL REGISTRATION: ClinicalTrials.gov No CTRI/2013/10/004121.
[Mh] Termos MeSH primário: Albendazol/uso terapêutico
Dietilcarbamazina/uso terapêutico
Filariose Linfática/tratamento farmacológico
Filariose Linfática/patologia
Filaricidas/uso terapêutico
Sistema Linfático/patologia
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Albendazol/administração & dosagem
Animais
Infecções Assintomáticas
Criança
Pré-Escolar
Dietilcarbamazina/administração & dosagem
Filariose Linfática/parasitologia
Feminino
Seres Humanos
Índia
Linfedema/tratamento farmacológico
Linfedema/parasitologia
Linfocintigrafia
Masculino
Resultado do Tratamento
Wuchereria bancrofti/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Filaricides); F4216019LN (Albendazole); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171119
[Lr] Data última revisão:
171119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171024
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005631


  4 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28984121
[Ti] Título:Global programme to eliminate lymphatic filariasis: progress report, 2016.
[Ti] Título:Programme mondial pour l'élimination de la filariose lymphatique: rapport de situation, 2016..
[So] Source:Wkly Epidemiol Rec;92(40):594-607, 2017 10 06.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Anti-Helmínticos/uso terapêutico
Erradicação de Doenças
Filariose Linfática/prevenção & controle
Saúde Global
Doenças Negligenciadas/prevenção & controle
[Mh] Termos MeSH secundário: Albendazol/administração & dosagem
Dietilcarbamazina/administração & dosagem
Erradicação de Doenças/organização & administração
Erradicação de Doenças/estatística & dados numéricos
Quimioterapia Combinada/métodos
Filariose Linfática/tratamento farmacológico
Filariose Linfática/epidemiologia
Doenças Endêmicas/prevenção & controle
Doenças Endêmicas/estatística & dados numéricos
Seres Humanos
Ivermectina/administração & dosagem
Loíase/tratamento farmacológico
Loíase/epidemiologia
Loíase/prevenção & controle
Doenças Negligenciadas/tratamento farmacológico
Doenças Negligenciadas/epidemiologia
Oncocercose/tratamento farmacológico
Oncocercose/epidemiologia
Oncocercose/prevenção & controle
Avaliação de Programas e Projetos de Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthelmintics); 70288-86-7 (Ivermectin); F4216019LN (Albendazole); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  5 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28922418
[Au] Autor:Lau CL; Sheridan S; Ryan S; Roineau M; Andreosso A; Fuimaono S; Tufa J; Graves PM
[Ad] Endereço:Department of Global Health, Research School of Population Health, The Australian National University, Canberra, Australia.
[Ti] Título:Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration.
[So] Source:PLoS Negl Trop Dis;11(9):e0005914, 2017 Sep.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Global Programme to Eliminate Lymphatic Filariasis (LF) aims to eliminate the disease as a public health problem by 2020 by conducting mass drug administration (MDA) and controlling morbidity. Once elimination targets have been reached, surveillance is critical for ensuring that programmatic gains are sustained, and challenges include timely identification of residual areas of transmission. WHO guidelines encourage cost-efficient surveillance, such as integration with other population-based surveys. In American Samoa, where LF is caused by Wuchereria bancrofti, and Aedes polynesiensis is the main vector, the LF elimination program has made significant progress. Seven rounds of MDA (albendazole and diethycarbamazine) were completed from 2000 to 2006, and Transmission Assessment Surveys were passed in 2010/2011 and 2015. However, a seroprevalence study using an adult serum bank collected in 2010 detected two potential residual foci of transmission, with Og4C3 antigen (Ag) prevalence of 30.8% and 15.6%. We conducted a follow up study in 2014 to verify if transmission was truly occurring by comparing seroprevalence between residents of suspected hotspots and residents of other villages. In adults from non-hotspot villages (N = 602), seroprevalence of Ag (ICT or Og4C3), Bm14 antibody (Ab) and Wb123 Ab were 1.2% (95% CI 0.6-2.6%), 9.6% (95% CI 7.5%-12.3%), and 10.5% (95% CI 7.6-14.3%), respectively. Comparatively, adult residents of Fagali'i (N = 38) had significantly higher seroprevalence of Ag (26.9%, 95% CI 17.3-39.4%), Bm14 Ab (43.4%, 95% CI 32.4-55.0%), and Wb123 Ab 55.2% (95% CI 39.6-69.8%). Adult residents of Ili'ili/Vaitogi/Futiga (N = 113) also had higher prevalence of Ag and Ab, but differences were not statistically significant. The presence of transmission was demonstrated by 1.1% Ag prevalence (95% CI 0.2% to 3.1%) in 283 children aged 7-13 years who lived in one of the suspected hotspots; and microfilaraemia in four individuals, all of whom lived in the suspected hotspots, including a 9 year old child. Our results provide field evidence that integrating LF surveillance with other surveys is effective and feasible for identifying potential hotspots, and conducting surveillance at worksites provides an efficient method of sampling large populations of adults.
[Mh] Termos MeSH primário: Filariose Linfática/epidemiologia
Filariose Linfática/transmissão
Filaricidas/administração & dosagem
Wuchereria bancrofti/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Aedes/imunologia
Albendazol/administração & dosagem
Albendazol/uso terapêutico
Samoa Americana/epidemiologia
Animais
Anticorpos Anti-Helmínticos/sangue
Antígenos de Helmintos/sangue
Criança
Pré-Escolar
Dietilcarbamazina/administração & dosagem
Dietilcarbamazina/uso terapêutico
Erradicação de Doenças
Esquema de Medicação
Filariose Linfática/imunologia
Filariose Linfática/parasitologia
Feminino
Filaricidas/uso terapêutico
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Prevalência
Estudos Soroepidemiológicos
Wuchereria bancrofti/isolamento & purificação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Helminth); 0 (Antigens, Helminth); 0 (Filaricides); F4216019LN (Albendazole); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005914


  6 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28851623
[Au] Autor:Ribeiro EL; Fragoso IT; Gomes FODS; Oliveira AC; Silva AKSE; Silva PME; Ciambarella BT; Ramos IPR; Peixoto CA
[Ad] Endereço:Laboratory of Ultrastructure, Aggeu Magalhães Research Center - CPqAM, Pernambuco, Brazil; Federal University of Pernambuco, Brazil.
[Ti] Título:Diethylcarbamazine: A potential treatment drug for pulmonary hypertension?
[So] Source:Toxicol Appl Pharmacol;333:92-99, 2017 Oct 15.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The present study demonstrated the potential effects of diethylcarbamazine (DEC) on monocrotaline (MCT)-induced pulmonary hypertension. MCT solution (600mg/kg) was administered once per week, and 50mg/kg body weight of DEC for 28days. Three C57Bl/6 male mice groups (n=10) were studied: Control; MCT and MCT /DEC. Echocardiography analysis was performed and lung tissues were collected for light microscopy (hematoxylin-eosin and Masson's trichrome staining), immunohistochemistry (αSMA, FADD, caspase 8, caspase 3, BAX, BCL2, cytochrome C and caspase 9) western blot (FADD, caspase 8, caspase 3, BAX, BCL2, cytochrome C and caspase 9) and qRt-PCR (COL-1α and αSMA). Echocardiography analysis demonstrated an increase in the pulmonary arterial blood flow gradient and velocity in the systole and RV area in the MCT28 group, while treatment with DEC resulted in a significant reduction in these parameters. Deposition of collagen fibers and αSMA staining around the pulmonary arteries was evident in the MCT28 group, while treatment with DEC reduced both. Western blot analysis revealed a decrease in BMPR2 in the MCT28 group, in contrast DEC treatment resulted in a significant increase in the level of BMPR2. DEC also significantly reduced the level of VEGF compared to the MCT28 group. Apoptosis extrinsic and intrinsic pathway markers were reduced in the MCT28 group. After treatment with DEC these levels returned to baseline. The results of this study indicate that DEC attenuates PH in an experimental monocrotaline-induced model by inhibiting a series of markers involved in cell proliferation/death.
[Mh] Termos MeSH primário: Dietilcarbamazina/uso terapêutico
Hipertensão Pulmonar/tratamento farmacológico
[Mh] Termos MeSH secundário: Actinas/genética
Animais
Apoptose/efeitos dos fármacos
Proteínas Reguladoras de Apoptose/metabolismo
Receptores de Proteínas Morfogenéticas Ósseas Tipo II/metabolismo
Colágeno Tipo I/genética
Dietilcarbamazina/farmacologia
Hipertensão Pulmonar/induzido quimicamente
Hipertensão Pulmonar/patologia
Hipertensão Pulmonar/fisiopatologia
Hipertrofia Ventricular Direita/induzido quimicamente
Hipertrofia Ventricular Direita/tratamento farmacológico
Hipertrofia Ventricular Direita/patologia
Hipertrofia Ventricular Direita/fisiopatologia
Pulmão/efeitos dos fármacos
Pulmão/metabolismo
Pulmão/patologia
Pulmão/fisiopatologia
Masculino
Camundongos Endogâmicos C57BL
Monocrotalina
Artéria Pulmonar/efeitos dos fármacos
Artéria Pulmonar/patologia
Função Ventricular Esquerda/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Actins); 0 (Apoptosis Regulatory Proteins); 0 (Collagen Type I); 0 (alpha-smooth muscle actin, mouse); 73077K8HYV (Monocrotaline); EC 2.7.11.30 (Bmpr2 protein, mouse); EC 2.7.11.30 (Bone Morphogenetic Protein Receptors, Type II); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE


  7 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723904
[Au] Autor:Ojha CR; Joshi B; Kc KP; Dumre SP; Yogi KK; Bhatta B; Adhikari T; Crowley K; Marasini BR
[Ad] Endereço:Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America.
[Ti] Título:Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
[So] Source:PLoS Negl Trop Dis;11(7):e0005788, 2017 Jul.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lymphatic filariasis (LF) is a neglected tropical disease transmitted by mosquitoes. Nepal has implemented a national effort to eliminate LF by 2020 through mass drug administration (MDA) using diethylcarbamazine (DEC) and albendazole (ALB). We assessed the impact of MDAs on LF in selected districts of Nepal after the recommended six MDA rounds had been completed. METHODOLOGY AND PRINCIPAL FINDINGS: Baseline surveys were conducted in seven districts and mapping data were used as baseline in the other three districts before starting MDA in 2009. LF antigen (Ag) prevalence ranged from 1.06% to 20% among districts included in the baseline and mapping study. The number of people who received DEC and ALB were recorded during each MDA round and population-based cluster surveys were conducted at least once in each district during the life of the program. The reported MDA coverage in five districts was consistently at least 65%. Two districts achieved the targeted coverage in four out of five rounds and the rest three districts achieved the target only in the first round. A pre-transmission assessment survey (pre-TAS) was conducted in one sentinel site and at least one spot check site in each of the districts after five MDA rounds. In pre-TAS, all the sites of five districts (Pyuthan, Arghakhanchi, Kaski, Bhaktapur, and Kathmandu) and all but one spot check site of Lalitpur district had LF Ag < 2% (ranging from 0.0% to 1.99%). Transmission assessment survey (TAS) was conducted in six evaluation units (EUs) consisting of six districts qualified on pre-TAS. Though MDA coverage of 65% was not achieved in three districts (Kathmandu, Lalitpur and Bhaktapur), Nepal government in consultation with World Health Organization (WHO) decided to conduct TAS. All six EUs achieved the LF Ag threshold required to stop MDA in TAS, despite the low reported MDA coverage in those three districts. CONCLUSIONS: Although Nepal has achieved significant progress towards LF elimination, five rounds of MDA were not sufficient to disrupt the transmission cycle in all districts, probably because of high baseline prevalence.
[Mh] Termos MeSH primário: Transmissão de Doença Infecciosa/prevenção & controle
Tratamento Farmacológico/métodos
Filariose Linfática/epidemiologia
Filariose Linfática/prevenção & controle
Filaricidas/administração & dosagem
[Mh] Termos MeSH secundário: Albendazol/administração & dosagem
Criança
Dietilcarbamazina/administração & dosagem
Uso de Medicamentos
Filariose Linfática/tratamento farmacológico
Filariose Linfática/transmissão
Feminino
Pesquisa sobre Serviços de Saúde
Seres Humanos
Masculino
Nepal/epidemiologia
Inquéritos e Questionários
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Filaricides); F4216019LN (Albendazole); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005788


  8 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28369129
[Au] Autor:Modi A; Gamit S; Jesalpura BS; Kurien G; Kosambiya JK
[Ad] Endereço:Department of Community Medicine, Government Medical College, Surat, Gujarat, India.
[Ti] Título:Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India.
[So] Source:PLoS Negl Trop Dis;11(4):e0005476, 2017 Apr.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Following the World Health Assembly resolution on Elimination of lymphatic filariasis (ELF) as a public health problem by the year 2020, a Global Program (GPELF) was launched in 1997 to help endemic countries to initiate national programs. The current strategy to interrupt transmission of LF, is administration of once-yearly, single-dose, two-drug regimen (Albendazole with Diethylcarbamazine (DEC) to be used in endemic areas with the goal of reaching 65% epidemiological coverage for 4-6 years. We report findings of independent assessment from year 2010 to 2015 for last six rounds, after initial five rounds of Mass Drug Administration (MDA) since 2005 for ELF in endemic area of Gujarat. METHODS: Independent assessment of MDA was performed to find coverage and compliance indicators, reasons for non-coverage and non-compliance in five Implementation Units (IUs). Pre, during and post MDA evaluations were done in three phases. The impact of MDA was measured by microfilaraemia survey. A total of eight sites, four random and four fixed sentinel sites were selected to calculate microfilaria rate (MF) per IUs per year. In years 2010 to 2015, we report results from 125,936 nocturnal blood smears and 17551 population in 120 selected clusters. Four clusters were selected per year in each of the five IUs for assessment of MDA round. RESULT: Post MDA survey showed drug coverage between 81%-88% and epidemiological coverage 77%-89% across years. Main reasons for non-coverage were drug administrator related (the team did not visit or missed people) while non-compliance was population related (fear of side effects, sickness, people forgot or absent). During MDA findings show that the directly observed consumption is considerably improved from 58% in 2010 to 82% in 2015. The knowledge about benefits of drug provided also increased from 59% to 90% over the years. The current MF rate is less than one in all IUs with an overall 68% percent decrease from baseline year 2005 to year 2015. The average MF rate of Gujarat is 0.44 for year 2015. CONCLUSIONS: The findings show that achieving adequate epidemiological and drug coverage is possible by actual field level operation of the program in large endemic areas. The results and feedback from independent assessment, performed regularly, could guide the policymakers and program managers for mid-term corrections and to frame strategies to enhance program. Monitoring of coverage and impact indicator together informs decisions for reaching end-point of MDA. The impact indicator- microfilaria rate in all IUs of South Gujarat Region has reached and remained less than one percent signaling end-points of MDA. Post MDA stringent monitoring in form of TAS is recommended to keep vigil on maintenance of elimination achieved.
[Mh] Termos MeSH primário: Albendazol/administração & dosagem
Dietilcarbamazina/administração & dosagem
Filariose Linfática/prevenção & controle
Filaricidas/administração & dosagem
Wuchereria bancrofti/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Erradicação de Doenças
Quimioterapia Combinada
Filariose Linfática/tratamento farmacológico
Filariose Linfática/epidemiologia
Doenças Endêmicas
Pesquisa sobre Serviços de Saúde
Seres Humanos
Índia/epidemiologia
Microfilárias
Avaliação de Programas e Projetos de Saúde
Vigilância de Evento Sentinela
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Filaricides); F4216019LN (Albendazole); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170516
[Lr] Data última revisão:
170516
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005476


  9 / 1713 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28329346
[Au] Autor:Herrick JA; Legrand F; Gounoue R; Nchinda G; Montavon C; Bopda J; Tchana SM; Ondigui BE; Nguluwe K; Fay MP; Makiya M; Metenou S; Nutman TB; Kamgno J; Klion AD
[Ad] Endereço:Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
[Ti] Título:Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
[So] Source:Clin Infect Dis;64(8):1017-1025, 2017 04 15.
[Is] ISSN:1537-6591
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Severe adverse reactions have been observed in individuals with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis, or ivermectin (IVM), which is used in mass drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa. In this study, posttreatment clinical and immunologic reactions were compared following single-dose therapy with DEC or IVM to assess whether these reactions have the same underlying pathophysiology. Methods: Twelve patients with loiasis and microfilarial counts <2000 mf/mL were randomized to receive single-dose DEC (8 mg/kg) or IVM (200 µg/kg). Clinical and laboratory assessments were performed at 4, 8, 24, 48, and 72 hours and 5, 7, 9, and 14 days posttreatment. Results: Posttreatment adverse events were similar following DEC or IVM, but peaked earlier in subjects who received DEC, consistent with a trend toward more rapid and complete microfilarial clearance in the DEC group. After a transient rise (post-IVM) or fall (post-DEC) in the first 24 hours posttreatment, the eosinophil count rose significantly in both groups, peaking at day 5 in the DEC group and day 9 in the IVM group. Serum interleukin 5 levels and eosinophil activation, as assessed by surface expression of CD69 and serum levels of eosinophil granule proteins, were increased posttreatment in both groups. Conclusions: Despite differences in eosinophil and lymphocyte counts during the first 24 hours posttreatment, the overall pattern of hematologic and immunologic changes suggest that posttreatment reactions following DEC and IVM share a common pathophysiology. Clinical Trials Registration: NCT01593722.
[Mh] Termos MeSH primário: Dietilcarbamazina/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Filaricidas/efeitos adversos
Ivermectina/efeitos adversos
Loíase/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Dietilcarbamazina/administração & dosagem
Feminino
Filaricidas/administração & dosagem
Seres Humanos
Ivermectina/administração & dosagem
Masculino
Meia-Idade
Projetos Piloto
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Filaricides); 70288-86-7 (Ivermectin); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170712
[Lr] Data última revisão:
170712
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1093/cid/cix016


  10 / 1713 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27914293
[Au] Autor:Fragoso IT; Ribeiro EL; Gomes FO; Donato MA; Silva AK; Oliveira AC; Araújo SM; Barbosa KP; Santos LA; Peixoto CA
[Ad] Endereço:Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz, CPqAM/FIOCRUZ, Brazil. Electronic address: ingridtavaresdelima@gmail.com.
[Ti] Título:Diethylcarbamazine attenuates LPS-induced acute lung injury in mice by apoptosis of inflammatory cells.
[So] Source:Pharmacol Rep;69(1):81-89, 2017 Feb.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute lung injury (ALI) is characterized by extensive neutrophil infiltration, and apoptosis delay considered part of the pathogenesis of the condition. Despite great advances in treatment strategies, few effective therapies are known for ALI. Diethylcarbamazine (DEC) is used against lymphatic filariasis, a number of studies have described its anti-inflammatory activities and pro-apoptotic effect. These properties have been associated with nuclear factor kappa-B inactivation. The aim of the present study was to investigate the effect of DEC on ALI induced by lipopolysaccharide (LPS) in mice. METHODS: DEC effect was evaluated by histological and ultrastructural analysis, immunohistochemistry and western blot (WB). Also TUNEL assays were performed and as well as myeloperoxidase (MPO) levels and nitric oxide (NO) were measured. RESULTS: The results demonstrate that LPS induced histological and ultrastructural changes with tissue damage, intense cell infiltration and pulmonary edema, and also increased levels of MPO and NO. DEC reversed these effects, confirming its anti-inflammatory action. DEC pro-apoptotic activity was also evaluated. The expression of TUNEL-positive cells and caspase-3 was increased in DEC treated group. Furthermore, immunohistochemical and WB analysis showed that DEC increased the expression of pro-apoptotic proteins in both the intrinsic (Bax, cytochrome c and caspase-9) and the extrinsic pathways of apoptosis (Fas, FADD and caspase-8). Additionally, DEC reduced the expression of the anti-apoptotic protein Bcl-2. CONCLUSION: Our results suggest that DEC attenuates ALI through the prevention of inflammatory cells accumulation by stimulating apoptosis. DEC accelerates the resolution of inflammation and may be a potential pharmacological treatment for ALI.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/prevenção & controle
Apoptose/efeitos dos fármacos
Dietilcarbamazina/uso terapêutico
Mediadores da Inflamação/antagonistas & inibidores
Lipopolissacarídeos/toxicidade
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/induzido quimicamente
Lesão Pulmonar Aguda/metabolismo
Animais
Anti-Inflamatórios/farmacologia
Anti-Inflamatórios/uso terapêutico
Apoptose/fisiologia
Dietilcarbamazina/farmacologia
Inflamação/induzido quimicamente
Inflamação/metabolismo
Inflamação/prevenção & controle
Mediadores da Inflamação/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Inflammation Mediators); 0 (Lipopolysaccharides); V867Q8X3ZD (Diethylcarbamazine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170323
[Lr] Data última revisão:
170323
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161204
[St] Status:MEDLINE



página 1 de 172 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde